Pazopanib (Votrient®)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of advanced renal cell carcinoma
  • Advanced soft tissue sarcoma in patient who have received previous chemotherapy

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All non-FDA approved uses not listed in the approved indications

Dosing:

  • 800 mg once daily without food
  • 200 mg once daily for patient with moderate hepatic impairment
  • Not recommend for patient with severe hepatic impairment

Warning:

  • Severe and fatal hepatotoxicity was observed in clinical trial

Approval:

  • Initial approval 6 weeks
  • Renewal: 6 months

 

Last review date: December 2, 2013